Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback